Arbor Realty Trust, Inc. Announces Proposed Public Offering of Convertible Senior Notes due 2020
Nov 07, 2017 21:40 pm UTC| Business
UNIONDALE, N.Y., Nov. 07, 2017 -- Arbor Realty Trust, Inc. (the “Company”) (NYSE:ABR) today announced that it intends to offer, subject to market and other conditions, $125 million aggregate principal amount of...
Rapid7 Announces Third Quarter 2017 Financial Results
Nov 07, 2017 21:39 pm UTC| Business
Total revenue was $50.5 million, an increase of 25% year-over-yearGAAP loss from operations was ($13.0) million, non-GAAP loss from operations was ($6.8) millionDeferred revenue of $188.6 million, an increase of 26%...
Havertys Announces Quarterly Cash Dividend
Nov 07, 2017 21:39 pm UTC| Business
ATLANTA, Nov. 07, 2017 -- HAVERTYS (NYSE:HVT) (NYSE:HVT.A) announced today, November 7, 2017, that its board of directors declared a cash dividend to be paid on the outstanding shares of the two classes of $1 par value...
Actua Files Definitive Proxy Materials for Sale of Its Three Majority-Owned Businesses
Nov 07, 2017 21:30 pm UTC| Business
RADNOR, Pa., Nov. 07, 2017 -- Actua Corporation (Nasdaq:ACTA) (“Actua”) filed definitive proxy materials with the U.S. Securities and Exchange Commission (“SEC”) today in connection with its special meeting of...
Infinera to Participate in MKM Investor Conference
Nov 07, 2017 21:30 pm UTC| Business
SUNNYVALE, Calif., Nov. 07, 2017 -- Infinera Corporation (NASDAQ:INFN), a provider of Intelligent Transport Networks, announced that it will participate in the following webcasted investor conference: MKM...
Synaptics Reports Results for First Quarter Fiscal 2018
Nov 07, 2017 21:27 pm UTC| Business
Revenue of $417.4 millionGAAP net loss per share of $0.79 due primarily to acquisition related itemsNon-GAAP net income per diluted share of $1.03Consumer IoT acquisitions complete; solutions for infinity displays on track...
Alder BioPharmaceuticals® Announces Third Quarter 2017 Financial and Operating Results
Nov 07, 2017 21:24 pm UTC| Business
– PROMISE 2 pivotal trial completed enrollment and top-line data on track for 1H18 – – Eptinezumab Biologics License Application (BLA) submission on track for 2H18 – – Conference call scheduled for 5 p.m. ET today – ...
FDA Approval of Opdivo Injection Sparks Hope for Cancer Patients with Revolutionary Treatment Update